文献速递流行病学与生物统计新药、器械与细胞基因治疗研发

安慰剂、吲哚美辛、布洛芬和对乙酰氨基酚与早产儿血流动力学显著动脉导管未闭闭合的关联:系统综述与网状Meta分析

Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA · 2018-01-01

该系统综述与网状Meta分析纳入68项随机临床试验共4802名早产儿,评估吲哚美辛、布洛芬和对乙酰氨基酚不同方案对血流动力学显著动脉导管未闭(PDA)闭合的相对可能性及不良事件。结果显示高剂量口服布洛芬相比标准剂量静脉布洛芬或静脉吲哚美辛与更高的PDA闭合几率相关,安慰剂或不治疗未显著改变死亡、坏死性小肠结肠炎或脑室内出血的几率。

要点

  • 高剂量口服布洛芬与血流动力学显著PDA闭合几率高于标准剂量静脉布洛芬或静脉吲哚美辛。
  • 高剂量口服布洛芬在PDA闭合和预防手术结扎的排名中均居首位。
  • 安慰剂或不治疗与各药物治疗相比未显著改变死亡、NEC或IVH的几率。

核心结论

  • 高剂量口服布洛芬相比标准剂量静脉布洛芬或静脉吲哚美辛与更高的血流动力学显著PDA闭合可能性相关。
  • 安慰剂或不治疗未显著改变死亡、坏死性小肠结肠炎或脑室内出血的几率。

研究设计与样本

  • 系统综述与贝叶斯随机效应网状Meta分析,检索MEDLINE、Embase和Cochrane Central Register of Controlled Trials从建库至2015年8月15日,并于2017年12月31日更新,同时检索至2017年12月的会议论文集。
  • 纳入68项随机临床试验共4802名胎龄小于37周的早产儿,治疗为静脉或口服吲哚美辛、布洛芬或对乙酰氨基酚相互比较或与安慰剂/不治疗比较。

主要发现

  • 共68项随机临床试验4802名婴儿,使用14种不同的吲哚美辛、布洛芬或对乙酰氨基酚治疗方案。
  • 总体PDA闭合率为67.4%(2867/4256名婴儿)。
  • 高剂量口服布洛芬相比标准剂量静脉布洛芬的PDA闭合OR为3.59(95% CrI 1.64-8.17),绝对风险差为每1000名婴儿多199例(95% CrI 95-258)。
  • 高剂量口服布洛芬相比标准剂量静脉吲哚美辛的PDA闭合OR为2.35(95% CrI 1.08-5.31),绝对风险差为每1000名婴儿多124例(95% CrI 14-188)。
  • 基于排名统计,高剂量口服布洛芬在PDA闭合方面排名最佳(平均SUCRA 0.89,SD 0.12),在预防手术结扎方面平均SUCRA为0.98(SD 0.08)。

临床怎么用

  • 对于血流动力学显著PDA的早产儿,高剂量口服布洛芬可作为提高闭合可能性的药物治疗选择。
  • 安慰剂或不治疗未显著改变死亡、坏死性小肠结肠炎或脑室内出血的几率,支持保守管理策略的安全性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Despite increasing emphasis on conservative management of patent ductus arteriosus (PDA) in preterm infants, different pharmacotherapeutic interventions are used to treat those developing a hemodynamically significant PDA. OBJECTIVES: To estimate the relative likelihood of hemodynamically significant PDA closure with common pharmacotherapeutic interventions and to compare adverse event rates. DATA SOURCES AND STUDY SELECTION: The databases of MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception until August 15, 2015, and updated on December 31, 2017, along with conference proceedings up to December 2017. Randomized clinical trials that enrolled preterm infants with a gestational age younger than 37 weeks treated with intravenous or oral indomethacin, ibuprofen, or acetaminophen vs each other, placebo, or no treatment for a clinically or echocardiographically diagnosed hemodynamically significant PDA. DATA EXTRACTION AND SYNTHESIS: Data were independently extracted in pairs by 6 reviewers and synthesized with Bayesian random-effects network meta-analyses. MAIN OUTCOMES AND MEASURES: Primary outcome: hemodynamically significant PDA closure; secondary: included surgical closure, mortality, necrotizing enterocolitis, and intraventricular hemorrhage. RESULTS: In 68 randomized clinical trials of 4802 infants, 14 different variations of indomethacin, ibuprofen, or acetaminophen were used as treatment modalities. The overall PDA closure rate was 67.4% (2867 of 4256 infants). A high dose of oral ibuprofen was associated with a significantly higher odds of PDA closure vs a standard dose of intravenous ibuprofen (odds ratio [OR], 3.59; 95% credible interval [CrI], 1.64-8.17; absolute risk difference, 199 [95% CrI, 95-258] more per 1000 infants) and a standard dose of intravenous indomethacin (OR, 2.35 [95% CrI, 1.08-5.31]; absolute risk difference, 124 [95% CrI, 14-188] more per 1000 infants). Based on the ranking statistics, a high dose of oral ibuprofen ranked as the best pharmacotherapeutic option for PDA closure (mean surface under the cumulative ranking [SUCRA] curve, 0.89 [SD, 0.12]) and to prevent surgical PDA ligation (mean SUCRA, 0.98 [SD, 0.08]). There was no significant difference in the odds of mortality, necrotizing enterocolitis, or intraventricular hemorrhage with use of placebo or no treatment compared with any of the other treatment modalities. CONCLUSIONS AND RELEVANCE: A high dose of oral ibuprofen was associated with a higher likelihood of hemodynamically significant PDA closure vs standard doses of intravenous ibuprofen or intravenous indomethacin; placebo or no treatment did not significantly change the likelihood of mortality, necrotizing enterocolitis, or intraventricular hemorrhage. TRIAL REGISTRATION: PROSPERO Identifier: CRD42015015797.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Mitra S, Florez ID, Tamayo ME, et al. Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis. JAMA. 2018. PMID: 29584842. doi:10.1001/jama.2018.1896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。